BABYLON HOLDINGS LTD- CL A (BBLN) Stock Fundamental Analysis

NYSE:BBLN • JE00BQWMWC12

0.5504 USD
-0.09 (-13.99%)
At close: Jun 28, 2023
0.5598 USD
+0.01 (+1.71%)
After Hours: 6/28/2023, 8:04:01 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to BBLN. BBLN was compared to 35 industry peers in the Health Care Technology industry. BBLN may be in some trouble as it scores bad on both profitability and health. BBLN is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year BBLN has reported negative net income.
  • BBLN had a negative operating cash flow in the past year.
BBLN Yearly Net Income VS EBIT VS OCF VS FCFBBLN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 -100M -200M -300M

1.2 Ratios

  • BBLN has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BBLN Yearly ROA, ROE, ROICBBLN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 0 -100 -200 -300 -400

1.3 Margins

  • BBLN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BBLN Yearly Profit, Operating, Gross MarginsBBLN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 0 -200 -400 -600 -800 -1K

1

2. Health

2.1 Basic Checks

  • BBLN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, BBLN has more shares outstanding
  • BBLN has a worse debt/assets ratio than last year.
BBLN Yearly Shares OutstandingBBLN Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 20M 40M 60M 80M
BBLN Yearly Total Debt VS Total AssetsBBLN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 100M 200M 300M 400M

2.2 Solvency

  • BBLN has an Altman-Z score of -4.90. This is a bad value and indicates that BBLN is not financially healthy and even has some risk of bankruptcy.
  • BBLN has a Altman-Z score of -4.90. This is in the lower half of the industry: BBLN underperforms 79.07% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -4.9
ROIC/WACCN/A
WACC4.64%
BBLN Yearly LT Debt VS Equity VS FCFBBLN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 0 200M -200M

2.3 Liquidity

  • BBLN has a Current Ratio of 1.07. This is a normal value and indicates that BBLN is financially healthy and should not expect problems in meeting its short term obligations.
  • BBLN has a worse Current ratio (1.07) than 62.79% of its industry peers.
  • A Quick Ratio of 1.07 indicates that BBLN should not have too much problems paying its short term obligations.
  • With a Quick ratio value of 1.07, BBLN is not doing good in the industry: 62.79% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.07
Quick Ratio 1.07
BBLN Yearly Current Assets VS Current LiabilitesBBLN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 100M 200M 300M

7

3. Growth

3.1 Past

  • BBLN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -112.81%.
  • The Revenue has grown by 149.85% in the past year. This is a very strong growth!
  • The Revenue has been growing by 310.57% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-112.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.52%
Revenue 1Y (TTM)149.85%
Revenue growth 3Y310.57%
Revenue growth 5YN/A
Sales Q2Q%16.77%

3.2 Future

  • Based on estimates for the next years, BBLN will show a very strong growth in Earnings Per Share. The EPS will grow by 21.15% on average per year.
  • The Revenue is expected to grow by 31.34% on average over the next years. This is a very strong growth
EPS Next Y57.13%
EPS Next 2Y32.22%
EPS Next 3Y21.15%
EPS Next 5YN/A
Revenue Next Year11.12%
Revenue Next 2Y9.08%
Revenue Next 3Y14.59%
Revenue Next 5Y31.34%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
BBLN Yearly Revenue VS EstimatesBBLN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 1B 2B 3B
BBLN Yearly EPS VS EstimatesBBLN Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 -5 -10 -15 -20

1

4. Valuation

4.1 Price/Earnings Ratio

  • BBLN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year BBLN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BBLN Price Earnings VS Forward Price EarningsBBLN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BBLN Per share dataBBLN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60

4.3 Compensation for Growth

  • A more expensive valuation may be justified as BBLN's earnings are expected to grow with 21.15% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.22%
EPS Next 3Y21.15%

0

5. Dividend

5.1 Amount

  • No dividends for BBLN!.
Industry RankSector Rank
Dividend Yield N/A

BABYLON HOLDINGS LTD- CL A

NYSE:BBLN (6/28/2023, 8:04:01 PM)

After market: 0.5598 +0.01 (+1.71%)

0.5504

-0.09 (-13.99%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)05-10
Earnings (Next)08-07
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners13.22%
Ins Owner Change0%
Market Cap14.08M
Revenue(TTM)1.98B
Net Income(TTM)-531.65M
Analysts40
Price Target7.65 (1289.9%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.99%
Min EPS beat(2)0.13%
Max EPS beat(2)9.85%
EPS beat(4)3
Avg EPS beat(4)2.78%
Min EPS beat(4)-1.28%
Max EPS beat(4)9.85%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)132.53%
Min Revenue beat(2)-9.58%
Max Revenue beat(2)274.65%
Revenue beat(4)2
Avg Revenue beat(4)66.81%
Min Revenue beat(4)-9.58%
Max Revenue beat(4)274.65%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-42.31%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.48%
EPS NY rev (1m)0%
EPS NY rev (3m)35.53%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-9.08%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-14.3%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.01
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-18.28
EYN/A
EPS(NY)-5.54
Fwd EYN/A
FCF(TTM)-13.24
FCFYN/A
OCF(TTM)-13.36
OCFYN/A
SpS77.2
BVpS-12.31
TBVpS-12.31
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover9.5
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 79%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.07
Quick Ratio 1.07
Altman-Z -4.9
F-Score3
WACC4.64%
ROIC/WACCN/A
Cap/Depr(3y)358.28%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-112.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.52%
EPS Next Y57.13%
EPS Next 2Y32.22%
EPS Next 3Y21.15%
EPS Next 5YN/A
Revenue 1Y (TTM)149.85%
Revenue growth 3Y310.57%
Revenue growth 5YN/A
Sales Q2Q%16.77%
Revenue Next Year11.12%
Revenue Next 2Y9.08%
Revenue Next 3Y14.59%
Revenue Next 5Y31.34%
EBIT growth 1Y4.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year68.12%
EBIT Next 3Y26.85%
EBIT Next 5Y20.95%
FCF growth 1Y-72.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-96.58%
OCF growth 3YN/A
OCF growth 5YN/A

BABYLON HOLDINGS LTD- CL A / BBLN FAQ

What is the ChartMill fundamental rating of BABYLON HOLDINGS LTD- CL A (BBLN) stock?

ChartMill assigns a fundamental rating of 2 / 10 to BBLN.


Can you provide the valuation status for BABYLON HOLDINGS LTD- CL A?

ChartMill assigns a valuation rating of 0 / 10 to BABYLON HOLDINGS LTD- CL A (BBLN). This can be considered as Overvalued.


Can you provide the profitability details for BABYLON HOLDINGS LTD- CL A?

BABYLON HOLDINGS LTD- CL A (BBLN) has a profitability rating of 1 / 10.


What is the earnings growth outlook for BABYLON HOLDINGS LTD- CL A?

The Earnings per Share (EPS) of BABYLON HOLDINGS LTD- CL A (BBLN) is expected to grow by 57.13% in the next year.